Activity and Safety of Tegafur, Gimeracil, and Oteracil Potassium for Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

In clinical practice, tegafur, gimeracil, and oteracil potassium (S-1) therapy is commonly administered to treat nasopharyngeal carcinoma (NPC). However, its efficacy and safety remain controversial in both randomized controlled trials (RCTs) and non-RCTs. We aimed to evaluate the efficacy and safet...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology 2021, Vol.2021, p.6690275-15
Main Authors: Zhang, Ximing, Tian, Xiumei, Wei, Yuezi, Deng, Hao, Ma, Lichun, Chen, Ziyang
Format: Article
Language:English
Subjects:
Analysis
Bias
Cancer
Carcinoma
Care and treatment
Chemotherapy
Health aspects
Meta-analysis
Mortality
Potassium
Radiation therapy
Radiotherapy
Review
Risk assessment
Safety and security measures
Systematic review
Throat cancer
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In clinical practice, tegafur, gimeracil, and oteracil potassium (S-1) therapy is commonly administered to treat nasopharyngeal carcinoma (NPC). However, its efficacy and safety remain controversial in both randomized controlled trials (RCTs) and non-RCTs. We aimed to evaluate the efficacy and safety of S-1 treatment for NPC. We searched PubMed, Ovid, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, and VIP databases for RCTs of chemotherapy with or without S-1 for NPC, from 2001 to 2020. A meta-analysis was performed using RevMan5.3 and Stata15. Randomized controlled trials published in journals were included irrespective of blinding and language used. Patients were diagnosed with NPC through a clinicopathological examination; patients of all cancer stages and ages were included. Overall, 25 trials and 1858 patients were included. There were significant differences in the complete remission (OR = 2.42, 95% CI (1.88–3.10), P
ISSN:1687-8450
1687-8450
DOI:10.1155/2021/6690275